Survey data found that better diagnosis and treatment methods are needed among patients with chronic cough in Japan due to the prevalent nature of the condition.
A web-based survey used to identify the prevalence estimate and characteristics of patients with chronic cough and subacute cough in Japan provides new information about an otherwise poorly studied population, reported BMJ Open Respiratory Research.
Previous research estimated that the prevalence of cough in Japan is 10.2% and that 23.2% of the cough population experienced chronic cough. The same research reported that more than 60% of patients with cough reported that they did not see a physician for their condition.
The current study sought to supplement previous research regarding prevalence and characteristics of patients with chronic cough. Data were used to compare characteristics and cough severity among patients with chronic cough who reported low satisfaction rates with treatment effectiveness and summarize causes and treatment use among patients with chronic cough.
Data regarding chronic cough status and cough-specific characteristics and experience were gleaned from an observational, cross-sectional online 2019 Japan National Health and Wellness Survey and a supplemental chronic cough survey. The study population consisted of 378 patients with subacute cough who self-reported having cough for 3—8 weeks and 568 patients with chronic cough who self-reported having cough for more than 8 weeks during any period in the past 12 months.
Findings showed:
The study data suggests that an unmet need for better diagnosis and treatments for chronic cough exists and should be mitigated, as cough is the most common reason for outpatient clinic and hospital visits in Japan. Mitigation strategies are especially critical for those who reported low satisfaction rates in treatment effectiveness and experienced worse cough severity.
Reference
Tobe K, Kubo T, Okuyama K, et al. Web-based survey to evaluate the prevalence of chronic and subacute cough and patient characteristics in Japan. BMJ Open Respir Res. 2021;8(1):e000832. doi:10.1136/bmjresp-2020-000832
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More